Ravasio, R., Viti, R., & Roscini, A. S. (2023). Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy. AboutOpen, 10(1), 13–21. https://doi.org/10.33393/ao.2023.2515